The Swedish-American Life Science Summit 2013
The Swedish-American Life Science Summit 2013 is the ninth in a
series of summits, in an invitation-only format where we present a
program featuring some of the best known Life Science executives and
investors in the world.
The intense and exclusive two-day program includes high-level panel discussions, insights from keynote speakers as well as a few selected presentations by successful and promising Swedish companies.
It is our hope and ambition that the summit will serve to increase the amount of cross-border business between the largest market in the world, the United States, and one of the most important Life Science industry centers in Europe, Sweden.
In addition, over the last couple of years the summit has taken on an increasingly global nature, making the summit a true reflection of the Life Science industry today.
Chairman & Senior Advisory Board
The people behind the Swedish-American Life Science Summit combine a long experience in the US pharmaceutical industry and Wall Street with today’s financial services within the field of Life Science in both countries.
Barbro C. Ehnbom has been a pioneer in the Life Science industry throughout her whole career. She was one of the first female executives in several US pharmaceutical companies, a top analyst in Wall Street, followed by many years of investment banking. As a long time board member of the Swedish-American Chamber of Commerce and Chairman Emeritus of the Swedish Economist Group in New York, she has 30 years experience in organizing events between Sweden and the U.S., not only in the commercial field but also in academics, music, the arts and social entrepreneurship.
View Curriculum Vitae »
View article from Dagens Industri (pdf, 90Kb) »
Learn more about The Female Economist of the Year Scholarship »
Frederick Frank is Vice Chairman of Peter J. Solomon Company. Mr. Frank brings to the summit over forty-five years of experience. Before joining Peter J. Solomon Company Mr. Frank was Vice Chairman of Lehman Brothers and Barclays Capital. Prior to joining Lehman Brothers he was Director of research and a Director of Smith, Barney & Co. Inc. He serves on the Board of Directors of several public companies and has provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare service providers, medical device and nutraceutical industries, and has been involved in hundreds of financings and merger and acquisition transactions in the global health care industry.
View article from Biotech Sweden (hi-res jpg, 2Mb) »
Dr. William A. Haseltine, PhD, is Chairman of Haseltine Global Health, LLC, a virtual pharmaceutical company dedicated to developing new and more efficient means to develop new life saving drugs and medical devices. He is also President of the Haseltine Foundation for Medical Sciences and the Arts, a foundation that supports access to high quality health for the poor and middle class of developing countries and that also fosters a dialog between sciences and the arts. He is an Adjunct Professor at The Scripps Institute for Medical Research. Dr. Haseltine has an active career in both Science and Business. He was a professor at Harvard Medical School from 1976-1993 where he was the chair of two academic research departments. He is well known for his pioneering work on cancer and HIV/AIDS. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and CEO of the Company until 2004. He is also the founder of seven other successful biotechnology companies. He serves as an advisor to CMEA, a venture capital company, and to several biotechnology and pharmaceutical companies.
Dr. Hans Wigzell, M.D., Ph.D., is Professor emeritus in Immunology at the Department of Microbiology, Tumour and Cell Biology at Karolinska Institutet since 2005. He is Chairman of Karolinska Development AB and board member of Swedish Orphan Biovitrum and a member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences. Dr. Wigzell was the President of Karolinska Institutet 1995-2003. From 1986 to 1991 he was head of first the National Bacteriological Laboratory and then its successor Swedish Institute for Infectious Disease Control. He is a member of the Board of the Karolinska Development AB (Chairman), RaySearch AB, Humabs, Intercell AG and AVIBiopharma as well as Chairman of Stockholm School of Entrepreneurship.
G. Steven Burrill is the Chief Executive Officer at Burrill & Company that is a diversified global financial services firm focused on the life sciences industry. G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves on the Boards of Directors of AliveCor, Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (TSX: NDQ), Proventys, Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.
Dr. Karin Hehenberger, M.D., Ph.D., is Executive Vice President & Chief Medical Officer at Coronado Biosciences and has over 12 years of experience in the healthcare industry. Most recently, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Prior to JDRF, Dr. Hehenberger worked at Johnson & Johnson as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, on the senior management team of Eyetech Pharmaceuticals, and earlier in her career as a strategic management consultant at McKinsey & Co. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School.
Lena Tibell is Founder & Managing Partner of Tibell & Associates, a consultancy firm within Life Science Business Management. She has over 20 years experience of International Sales & Marketing and Business Management in Life Science industry plus 10 years in Medical research and Drug analysis. Her experience covers Business Strategies, Market Assessments, Product Development and Launch, as well as Clinical Evaluations. Lena has senior competence in working with Distributors and Sales organizations, as well as Starting-up and Re-organizing sales companies. Prior to starting Tibell & Associates, she held positions as Business Manager at Hudson RCI and Louis Gibeck, Marketing Manager at Pharmacia Biotech and Clinical Development Engineer at a Swedish University Hospital.
Administration SALSS 2013Veronica Råberg-Schrello, Project Manager
Tel: +46 702 792 524
Veronica Råberg-Schrello holds a degree of Bachelor of Arts from the Stockholm University and is currently pursuing her second degree of Science at the Stockholm School of Economics (SSE). Prior to becoming Project Manager for SALSS 2013, Veronica worked in the Music & Event Management industry for several years, parallel to her studies. Half Swedish and half American, she enjoys intercultural exchange and has spent a year at the prestigious Bocconi University in Milan. At SSE, Veronica is the Head of a student-led consultancy and she has been working strategically within the Student Association since the beginning of her studies. She is also involved with the Female Economist Scholarship and on the board of the BBBnetwork.Veronica worked closely with 2012 Project Manager, Sana Alajmovic, all through last year's SALSS and is now enthusiastically looking forward getting to know the whole SALSS family.
Jonas Månsson has several years of experience in the event management industry, both in Sweden and abroad. He worked as Stockholm Coordinator for SALSS 2001 & 2012 and was the Project Manager of the prestigious Female Economist of the Year Scholarship Gala at Stockholm School of Economics 2011, 2012 & 2013. Jonas is also a professional singer and fluent in five languages.